Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gencia Corp
Meeting all primary and secondary endpoints in a pair of pivotal trials, Brickell says sofpironium bromide gel will be ready for FDA filing in mid-2022. The topical is already approved in Japan as Ecclock.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.
Since the mid-1950's getting "shots" has been a source of childhood terror. Now, small companies are looking at ways to deliver vaccines through the oral or nasal mucosa, or using needle-free skin delivery systems to take advantage of immune cells within the skin.
- Other Names / Subsidiaries
- Gencia Biotech
- Gencia LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.